APAC Clinical Trials Market Size and Shares with Report Analysis 2035

APAC Clinical Trials Market Size, Key Players with Growth and Insights

The APAC clinical trials market size was estimated at US$ 18.87 billion in 2025, projected to increase to US$ 20.42 billion in 2026 and reach US$ 41.33 billion by 2035, showing a healthy CAGR of 7.16% across the forecast years.

The APAC clinical trials market is expanding rapidly due to growing investment in life sciences research, increasing outsourcing of trials from Western countries, and supportive government policies. China and India are emerging as key hubs, driven by large, diverse patient populations and skilled medical professionals. Rising prevalence of chronic diseases and demand for innovative therapies further boost trial activities, positioning the region as a critical contributor to the global clinical research landscape.

Key Takeaways

• APAC clinical trials sector pushed the market to USD 18.87 billion by 2025.
• Long-term projections show USD 41.33 billion valuation by 2035.
• Growth is expected at a steady CAGR of 7.16% in between 2026 to 2035.
• The global clinical trials market, valued at USD 98.91 billion in 2026, is projected to reach USD 174.18 billion by 2035, growing at a CAGR of 5.7%.
• China dominated the APAC clinical trials market with a revenue share in 2024. 
• By phase, the phase 3 segment led the market with the largest revenue share in 2024.
• By phase, the phase 2 segment is expected to grow at the fastest CAGR in the market during the forecast period.
• By study design, the interventional study segment held the largest market share in 2024 and is expected to grow at the fastest CAGR in the market during the forecast period.
• By indication, the oncology segment held the highest market share in 2024 and is expected to grow at the fastest CAGR in the market during the forecast period.

Key Indicators and Highlights

What are Clinical Trials?

The market is growing rapidly due to increasing R&D activities, large patient populations, and supportive government policies. The APAC clinical trials are research studies conducted in the region to evaluate the safety, efficacy, and outcomes of new drugs or medical treatments in local populations. The APAC clinical trials market is experiencing rapid growth due to increasing investments in healthcare infrastructure, a surge in demand for personalized medicine, and advancements in digital health technologies.

Countries like China and India are emerging as key hubs for clinical research, driven by their large and diverse patient population, cost-effective operations, and supportive regulatory environments. This expansion is further fueled by the rise of Contract research organizations (CROs) and the adoption of decentralized clinical trial models, enhancing efficiency and accessibility in the region.

APAC Clinical Trials Market Outlook

• Industry Growth Overview- The market is rapidly growing, driven by rising R&D investments, supportive government policies, cost-effective operations, skilled medical professionals, and increasing demand for innovative therapies across diverse patient populations.
• Sustainability Trends- The APAC clinical trials market is embracing sustainability through decentralized trials, digital data collection, reduced travel, eco-friendly practices, and resource optimization, aiming to minimize environmental impact while enhancing efficiency and patient accessibility.
• Major Investors- Major investors in the market include private equity, venture capital, pharmaceutical companies, and multinational corporations, funding R&D, expanding CROs, and enhancing infrastructure to drive growth and innovation.

APAC Clinical Trials Market Trends and Future Outlook

• Expansion of Decentralized Clinical Trials: Healthcare companies are adopting decentralized clinical trials across Asia Pacific. Remote patient monitoring, telemedicine, and electronic data capture are becoming common. These tools reduce travel needs and improve patient participation. Countries such as Australia, Japan, and South Korea are investing in digital health infrastructure. Better internet access and smartphone use are supporting faster recruitment and stronger patient engagement.
• Growing Investment in Early-Phase Research: Asia Pacific is attracting more early-phase clinical studies because of lower operational costs and skilled researchers. Global pharmaceutical and biotechnology companies are expanding partnerships with regional hospitals and research centers. China, India, and Singapore are strengthening research capabilities. Improved regulatory processes and advanced laboratory facilities are helping sponsors complete studies more efficiently and with better quality.
• Stronger Regional Collaboration: Cross-border collaboration is expected to increase across Asia Pacific clinical trials. Governments, research institutions, and pharmaceutical companies will work together on larger multinational studies. Harmonized regulatory standards may simplify approvals and improve study timelines. More investment in research infrastructure and workforce training will strengthen regional competitiveness. This will attract additional global sponsors seeking diverse patient populations.

How Can AI Affect the Market?

AI can significantly impact the APAC clinical trials market by accelerating patient recruitment, optimizing trial design, and improving data analysis. It enables predictive modeling, real-time monitoring, and personalized treatment strategies, reducing costs and timelines. AI-driven automation enhances accuracy in trial operations, while machine learning identifies patient cohorts and potential adverse effects more efficiently. Overall, AI adoption increases trial efficiency, supports decentralized models, and strengthens the region’s competitiveness in global clinical research.

What are the Government Initiatives in the APAC Clinical Trials Market in 2024?

• In June 2024, China’s NMPA proposed a fast-track approval process for overseas drugs addressing urgent medical needs, including clinical trial waivers and shorter inspections, and sought public feedback until July 24, 2024. Earlier in April 2024, it also aimed to expedite approvals for orphan drugs to meet rising patient demand.
• In 2024, the Australian government launched the Clinical Trials Activity Initiative, committing $750 million over 10 years to support trials targeting rare cancers, rare diseases, and unmet medical needs, as well as investigator-led international studies. This builds on earlier efforts to enhance Australia’s position in global clinical research, including the R&D refund scheme introduced in July 2021, which offers up to 43.5% cash refunds to incentivize research activities.

Clinical Trial Occurs in India

Segmental Insights

How does the Phase 3 Segment dominate the APAC Clinical Trials Market in 2024?

The phase 3 segment led the market with the largest revenue share in 2024 due to its critical role in confirming drug efficacy, monitoring side effects, and comparing new treatments with existing standards. These trials require a large patient population, longer duration, and greater investments. Additionally, increasing demand for late-stage clinical validation and prevalence of chronic diseases further the dominance of phase 3 trials in the market.

The phase 2 segment is projected to grow at the fastest CAGR during the forecast period due to the rising number of investigator-led and institution-based trials across the Asia-Pacific region. Favorable regulatory reforms, growing emphasis on targeted therapies, and increasing funding for early-stage research are accelerating phase 2 activities. Sponsors prefer this phase to assess drug efficacy and refine dosing before large-scale trials, making it a crucial step in advancing innovative treatment development efficiently.

Why Did the Interventional Study Segment Dominate the APAC Clinical Trials Market in 2024?

The interventional study segment dominated the market in 2024 and is expected to grow at the fastest CAGR due to its critical role in testing new treatments through controlled clinical settings. These studies provide reliable safety and efficacy data required for regulatory approvals. Increasing R&D investments, the rise of precision medicine, and advancements in digital trial technologies have further boosted interventional research. Additionally, growing patient enrollment and government support for innovative therapies are driving the market's continued expansion.

What made the Oncology Segment Dominant in the APAC Clinical Trials Market in 2024?

The oncology segment led the market in 2024 and is projected to grow fastest because of the increasing number of treatment-naïve cancer patients and expanding oncology research infrastructure across the Asia-Pacific. Supportive regulatory reforms, rising domestic biotech innovation, and growing participation in multinational cancer trials are driving the growth. Additionally, the focus on novel therapies, such as cell and gene treatment, continues to strengthen the region's position in global oncology clinical development.

Regional Insights

How is China contributing to the Expansion of the APAC Clinical Trials Market?

China dominated the market in 2024 due to its well-developed clinical research infrastructure, large pool of treatment-naïve patients, and growing expertise in biopharmaceutical innovation. Supportive government policies and streamlined regulatory processes have made the country a preferred hub for both domestic and international sponsors. Additionally, the adoption of advanced technologies, a skilled workforce, and collaboration between research institutes and pharmaceutical companies have strengthened China’s position as a leading center for clinical trials in the region.

In 2024, China registered 4,900 clinical trials (up 13.9% vs 2023). Of these, 2,539 (51.8%) were for new drug development, and 2,361 (48.2%) were bioequivalence studies.

Advanced Healthcare Infrastructure is Driving Japan

The Japan APAC clinical trials market is expanding due to its advanced healthcare infrastructure, strong regulatory support, and growing focus on innovative therapies. The country has a well-established network of hospitals and research centers, enabling efficient patient recruitment and high-quality data collection. Additionally, government initiatives encourage collaboration between pharmaceutical companies and academic institutions, while increasing investment in biotechnology and precision medicine drives the development of novel treatments, making Japan a key contributor to the growth of clinical research in the region.

About 1,500 clinical trials are active at any time in Japan. Credevo The clinical trials support services market earned USD 1,030.8 million in 2024, with Phase III trials generating the highest revenue.

Supportive Government Policies are Driving India

India’s market is increasing due to its large and diverse patient population, which enables faster recruitment for both early- and late-phase studies. The country offers cost-effective trial operations, skilled medical professionals, and an improved clinical research infrastructure. Supportive government policies, such as streamlined regulatory approvals and incentives for foreign sponsors, encourage more multinational and domestic trials. Additionally, growing focus on innovative therapies and increasing healthcare investments are driving India’s rising role in the regional clinical trials landscape.

India registered approximately 18,000 new clinical trials in 2024, a 50% rise from the previous year. Of 94,730+ trials registered since 2000 in CTRI, 79% focus on non-communicable diseases.

Global Clinical Trials Market Growth

The global clinical trials market is valued at USD 98.91 billion in 2026 and is projected to reach USD 174.18 billion by 2035, growing at a compound annual growth rate (CAGR) of 5.7% over the forecast period from 2026 to 2035.

APAC Clinical Trials Market Value Chain Analysis

Clinical Trial

• APAC clinical trials are growing due to large patient populations.
• Cost-effective operations and supportive regulations boost early-stage trial activities.

Regulatory Approvals

• Clinical trials in APAC need approval from each country’s regulatory authority.
• Authorities like India’s CDSCO and Japan’s PMDA have their own specific timelines and requirements.

Patient Support and Services

• APAC clinical trials provide patient support through concierge services, virtual platforms, and educational resources.
• Remote nursing and partnerships with local advocacy groups help address logistical, cultural, and geographical challenges.

Top Vendors and their Offerings

• IQVIA Inc.- IQVIA provides advanced data analytics, clinical research services, real-world evidence solutions, and technology-driven platforms to support pharmaceutical, biotechnology, and healthcare companies in drug development, commercialization, and patient-centric healthcare strategies.
• Parexel International Corporation- Parexel International provides end-to-end clinical development, pharmacovigilance, and regulatory support, along with patient recruitment, real-world evidence, and strategic consulting services, helping biopharma companies efficiently bring new therapies to global markets.
• Thermo Fisher Scientific Inc.- Thermo Fisher Scientific provides comprehensive life sciences solutions, including clinical trial support, sample management, analytical services, and laboratory technologies, enabling pharmaceutical and biotech companies to streamline research, accelerate drug development, and ensure regulatory compliance.
• ICON Plc.- ICON Plc. Provides outsourced development and commercialization services, including biometrics, medical imaging, clinical trial optimization, and consulting, supporting pharmaceutical, biotechnology, and medical device companies in accelerating clinical programs globally.

Top Companies in the APAC Clinical Trials Market

• LabCorp
• Syneos Health
• Novotech
• Avance Clinical
• AbbVie
• Merck Sharp & Dohme LLC

Latest Announcement by Industry Leader

In July 2026, Japan and the UK announced a research partnership to advance cancer treatment across all age groups. Professor Lucy Chappell, CEO of the NIHR, said: "We are delighted to partner with the Japan Agency for Medical Research and Development on this vital initiative. Despite significant progress, cancer remains the leading cause of death by disease among children and young adults in England, and there is a need for more effective, targeted treatments. By combining the world-class expertise of the UK and Japan, we can accelerate the pace of discovery. This partnership aligns clearly with the Government’s National Cancer Plan. It breaks down barriers to clinical trials and brings us closer to delivering innovative therapies that will save and improve young lives."

Recent Developments in the Market

• In August 2026, Fujifilm and Taiho Pharmaceutical partnered to improve how they make next-generation antibody-drug conjugates (ADCs). They will use Araris Biotech's AraLinQT™ technology to make Taiho’s drug candidates. This deal unites Taiho's drug discovery skills with Fujifilm's manufacturing expertise.
• In May 2026, the Indian Council of Medical Research hosted the 1st ICMR Annual Clinical Trial Meet on May 20, 2026. Centered on integrative medicine trials, the event launched new ethical review guidelines and aimed to improve India's medical research standards.

Recent Developments in the APAC Clinical Trials Market

• In February 2025, LabConnect formed a multi-year partnership with Australian Clinical Labs’ Specialised Trials to boost clinical trial support in Australia and the APAC region. The alliance leverages both organizations’ strengths to meet growing demand from pharmaceutical, biotech, and research institutions, ultimately facilitating patient access to essential medications.
• In December 2024, Sunway Healthcare Group partnered with Syneos Health to strengthen clinical trial operations in Malaysia. The collaboration aims to improve patient access, streamline operations, offer specialized expertise, and engage diverse patient populations across multiple therapeutic areas and trial phases.

Segments Covered in the Report

By Phase

• Phase 1
• Phase 2
• Phase 3
• Phase 4

By Study Design

• Observational Study
• Interventional Study
• Expanded Access Study

By Indication

• Autoimmune/Inflammation
  • Rheumatoid arthritis
  • Multiple Sclerosis
  • Osteoarthritis
  • Irritable Bowel Syndrome (IBS)
  • Others
• Pain Management
  • Chronic Pain
  • Acute Pain
  • Oncology
  • Blood Cancer
  • Solid Tumors
  • Other
• CNS Condition
  • Epilepsy
  • Parkinson's Disease (PD)
  • Huntington's Disease
  • Stroke
  • Traumatic Brain Injury (TBI)
  • Amyotrophic Lateral Sclerosis (ALS)
  • Muscle Regeneration
  • Others
• Diabetes
  • Obesity
  • Cardiovascular
  • Others

By Region 

• North America
  • U.S.
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Thailand
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait